![Parent Project Muscular Dystrophy](/img/default-banner.jpg)
- Видео 662
- Просмотров 2 005 340
Parent Project Muscular Dystrophy
США
Добавлен 15 авг 2007
Parent Project Muscular Dystrophy (PPMD) is the largest nonprofit organization in the United States focused entirely on Duchenne muscular dystrophy.
We take a comprehensive approach in the fight against Duchenne-funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options. Only this comprehensive approach will lead to the day that 100% of those diagnosed can turn to a treatment that will lead to the end of Duchenne muscular dystrophy.
We take a comprehensive approach in the fight against Duchenne-funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options. Only this comprehensive approach will lead to the day that 100% of those diagnosed can turn to a treatment that will lead to the end of Duchenne muscular dystrophy.
PPMD 2024 Annual Conference: Day 1 - Newly Diagnosed & Duchenne 101 Discussions
Deciphering Duchenne: An Understanding of What I will Hear & how to Interpret: Kathi Kinnett, MSN, APRN, PPMD
Navigating Your Experience at PPMD's Annual Conference: Colleen Labbadia, PPMD Parent Advocate
The Duchenne Registry: Citizen Science: Kayla Banks, MS, CGC, PPMD
Family Dynamics: Thriving, Not just Living with Duchenne: James Poysky, PhD, Baylor College of Medicine
Discussion and Q&A
Navigating Your Experience at PPMD's Annual Conference: Colleen Labbadia, PPMD Parent Advocate
The Duchenne Registry: Citizen Science: Kayla Banks, MS, CGC, PPMD
Family Dynamics: Thriving, Not just Living with Duchenne: James Poysky, PhD, Baylor College of Medicine
Discussion and Q&A
Просмотров: 37
Видео
PPMD 2024 Annual Conference: Day 3 - OptimizeDMD: Moving the Dial in Endocrinology & Bone Issues
Просмотров 50День назад
OptimizeDMD: Moving the Dial in Endocrinology & Bone Issues in Duchenne Leanne Ward, MD, FRCPC, Children’s Hospital of Eastern Ontario Maitea Guridi, PhD, Roche
PPMD 2024 Annual Conference: Day 2 - KEYNOTE: Resilience
Просмотров 18День назад
Pat Moeschen, Advisor, PPMD Adult Advisory Committee
PPMD 2024 Annual Conference: Day 1 - Reporting to You on PPMD Professional Meetings
Просмотров 49День назад
Reporting to You on PPMD Professional Meetings: Kathi Kinnett, MSN, APRN, PPMD (Moderator) PPMD's Cardiac Meetings: Linda Cripe, MD, Nationwide Children's Hospital PPMD's Endocrinology Meeting: Leanne Ward, MD, University of Ottawa PPMD's Duchenne Healthcare Professionals Summit: Emma Ciafaloni, MD, University of Rochester
PPMD 2024 Annual Conference: Day 3 - Next Steps and Closing Remarks
Просмотров 15День назад
Pat Furlong, Founding President & CEO, PPMD
PPMD 2024 Annual Conference: Day 2 - Decision Making around Steroids, Weight, and Nutrition
Просмотров 37День назад
Decision Making around Steroids, Weight, & Nutrition Nadia Merchant, MD, Children's National Hospital Emma Ciafaloni, MD, University of Rochester Robert Benjamin, MD, Duke University Kiera Berggren, SLP, VCU Health
PPMD 2024 Annual Conference: Day 2 - Research Row: Strategies to Restore Dystrophin
Просмотров 110День назад
Research Row: Strategies to Restore Dystrophin Annemieke Aartsma-Rus, PhD, University of Leiden (Moderator) Avidity Biosciences - AOC 1044: Henry Nchienzia, PhD, Avidity Biosciences Biomarin - BMN 351: Peter Velzquez, PhD, BioMarin Pharmaceutical Inc. Dyne Therapeutics - DYNE-251: John Cox, MBA, Dyne Therapeutics Entrada Therapeutics - ENTR-601-44: Mahasweta Girgenrath, PhD, Entrada Therapeutic...
PPMD 2024 Annual Conference: Day 3 - Your Citizen Science at Work: How Pain Impacts Quality of Life
Просмотров 22День назад
Your Citizen Science at Work: How Pain Impacts Quality of Life Ann Martin, MS, CGG, PPMD Shannon Grabich, PhD, MS, Sarepta Therapeutics
PPMD 2024 Annual Conference: Day 3 - Clinical Trials: A Panel Discussion on the Developmental Path
Просмотров 69День назад
Erica Goude, MS,CCRP, UC Davis Medical Center (Moderator) Paolo Bettica, MD, PhD, Italfarmaco Naz Dastgir, DO, RegenxBIO Joanne Donovan, MD, PhD, Edgewise Therapeutics Kevin Flanigan, MD, Nationwide Children's Hospital Erik Henricson, PhD, MPH, UC Davis Health
PPMD 2024 Annual Conference: Day 3 - Research Row: PPMD Moving the Needle
Просмотров 126День назад
Research Row: PPMD Moving the Needle Moderator: Eric Camino, PhD, PPMD Casey Childers, DO, PhD, Kinea Bio Frank Gleeson, MBA, Co-Founder & CEO, Satellos Stan Nelson, MD, UCLA Rita Perlingeiro, Ph.D. University of Minnesota Barry Byrne, MD, PhD, University of Florida
PPMD 2024 Annual Conference: Day 3 - What really Matters: A Town Hall on Life, Living, and Hope
Просмотров 16День назад
What really Matters: A Town Hall on Life, Living, and Hope Rachel Callander, Patient Experience Advocate Jennifer Tullio, PPMD Parent Advocate Limca Jhaveri, PPMD Parent Advocate Jen Schwartz, PPMD Parent Advocate Clare Perrin, PPMD Parent & Advocate Chris Cate, PPMD Parent Advocate
PPMD 2024 Annual Conference: Day 3 - Panel Conversation: Enhancing Social Experiences
Просмотров 28День назад
Susan Apkon, MD, Children's Hospital Colorado (Moderator) Tina Duong, MPT, PhD, Stanford University School of Medicine Adith Thumallapali, PPMD Adult Advisory Committee DeAnne Friar, PPMD Board Memeber Jason Vertin, PPMD Advocate & Duchenne Parent Andrea Colucci, ARCH & Children's Hospital Colorado
PPMD 2024 Annual Conference: Day 1 - 30 Years Fighting for Every Future
Просмотров 49День назад
PPMD 30 Opening Remarks from Pat Furlong, Founding President & CEO, PPMD
PPMD 2024 Annual Conference: Day 1 - Outcome Measures: The Eras Tour
Просмотров 79День назад
PPMD 2024 Annual Conference: Day 1 - Outcome Measures: The Eras Tour
PPMD 2024 Annual Conference: Day 3 - Research Row: Approaches to Alter Progression
Просмотров 137День назад
PPMD 2024 Annual Conference: Day 3 - Research Row: Approaches to Alter Progression
PPMD 2024 Annual Conference: Day 2 - KEYNOTE - A Reflection on Progress and Hope
Просмотров 29День назад
PPMD 2024 Annual Conference: Day 2 - KEYNOTE - A Reflection on Progress and Hope
PPMD 2024 Annual Conference: Day 3 - Panel Conversation: The Little Things Matter
Просмотров 8День назад
PPMD 2024 Annual Conference: Day 3 - Panel Conversation: The Little Things Matter
PPMD 2024 Annual Conference: Day 1 - Community Conversation With Pfizer
Просмотров 103День назад
PPMD 2024 Annual Conference: Day 1 - Community Conversation With Pfizer
PPMD 2024 Annual Conference: Day 2 - How Managing Behaviors Impacts Your Quality of Life
Просмотров 22День назад
Panel Discussion: James Poysky, PhD, Baylor College of Medicine (Moderator) Natalie Truba, PhD, Nationwide Children's Hospital Andrea Miele, PhD, Children's Hospital Colorado Brandon Kozar, PsyD, MBA, Nationwide Children's Hospital
PPMD 2024 Annual Conference: Day 1 - Navigating the Approved Therapy Landscape
Просмотров 208День назад
Navigating the Approved Therapy Landscape: Rachel Schrader, MS, APRN, CPNP-PC, PPMD Newly Approved Therapies - Agamree: Serene Nelson, PharmD, BCCCP, BCMAS, Catalyst Pharmaceuticals Newly Approved Therapies - Duvyzat: Scott Baver, PhD, ITF Therapeutics Newly Approved Therapies - Elevidys Expanded Label: Craig McDonald, MD, UC Davis Current Approved Therapies Panel Discussion Rachel Schrader, MS...
PPMD 2024 Annual Conference: Day 1 - Building Your Community - It Takes a Team
Просмотров 17День назад
PPMD 2024 Annual Conference: Day 1 - Building Your Community - It Takes a Team
PPMD 2024 Annual Conference: Day 2 - Sleep & Behavior: How They Impact Each Other
Просмотров 21День назад
PPMD 2024 Annual Conference: Day 2 - Sleep & Behavior: How They Impact Each Other
PPMD 2024 Annual Conference: Day 3 - Making Friends and ImPAACting People: A PAAC Presentation
Просмотров 3014 дней назад
PPMD 2024 Annual Conference: Day 3 - Making Friends and ImPAACting People: A PAAC Presentation
Webinar: Community Progress in Duchenne Newborn Screening
Просмотров 1583 месяца назад
Webinar: Community Progress in Duchenne Newborn Screening
Webinar: Community Update with ITF Therapeutics: Introducing DUVYZAT™ (givinostat) [March 2024]
Просмотров 1,9 тыс.4 месяца назад
Webinar: Community Update with ITF Therapeutics: Introducing DUVYZAT™ (givinostat) [March 2024]
Webinar: Sarepta Therapeutics - Data update from MOMENTUM study, SRP-5051 [Mar 2024]
Просмотров 5194 месяца назад
Webinar: Sarepta Therapeutics - Data update from MOMENTUM study, SRP-5051 [Mar 2024]
Webinar: NS Pharma - Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 (Mar 2024)
Просмотров 3284 месяца назад
Webinar: NS Pharma - Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 (Mar 2024)
Webinar: PTC Therapeutics - EMFLAZA® Landscape in 2024
Просмотров 3035 месяцев назад
Webinar: PTC Therapeutics - EMFLAZA® Landscape in 2024
Webinar: Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences [Feb 2024]
Просмотров 3645 месяцев назад
Webinar: Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences [Feb 2024]
Okay
One sock😅😅
Entre los tres y los seis años de edad, pueden observarse indicios de una mejoría transitoria, conocida como "fase de la luna de miel", a la que sigue gradualmente un deterioro incesante, que confina al paciente a una silla de ruedas hacia los 13 años aproximadamente. La mayoría de los pacientes con DMD mueren a finales de la adolescencia En la exploración física, se destacaba un regular estado general, irritabilidad, signos de desnutrición, tiraje leve e hipoventilación en la auscultación respiratoria, distensión abdominal y hepatomegalia de 1-2 cm y neumonía en lóbulos superior derecho e inferior izquierdo en la radiografía de tórax. En las pruebas complementarias iniciales, se detectó anemia leve. Ante estos hallazgos, se planteó la posibilidad de una afectación muscular, por lo que se solicitó CK sérica, y EMG con patrón miopático, lo que confirmó el diagnóstico de miopatía. Los estudios cardiológico, oftalmológico y resonancia magnética nuclear cerebral fueron normales. Se planteó, como primera posibilidad diagnóstica, la DMD. Para confirmar el diagnóstico, se realizó la técnica de amplificación de sondas dependiente de ligandos múltiples que no detectó deleción ni duplicación en ninguno de los 79 exones del gen de la distrofina. La biopsia muscular evidenció un patrón distrófico e inmunofenotipo con ausencia completa de distrofina compatible con DMD Consideramos que se trata de una mutación “de novo”, ya que el estudio genético realizado con la misma técnica a la madre no detectó esta mutación ni ninguna otra; además, su CK era normal. No ha presentado patología respiratoria ni cardiológica relevante. A nivel nutricional, precisó suplementos dietéticos al inicio y mantuvo el peso y la talla entre percentiles 10-25; actualmente, tiene una dieta variada no suplementada. En el momento del diagnóstico, nuestro paciente aún no había desarrollado la capacidad de deambular sin ayuda. Dado que la edad de 18 meses se considera el límite máximo de la normalidad en la mayoría de las escalas de desarrollo psicomotor es probable que la DMD hubiera pasado inadvertida durante unos meses más. El fallo en el crecimiento, a pesar de no ser típico en la DMD, está descrito en algunos casos como forma de presentación Consideramos que este paciente se trata de un caso esporádico de DMD, causado por una mutación. Debido a esto, ante una elevada sospecha clínica, es recomendable la realización de una biopsia muscular para confirmar el diagnóstico si el test genético inicial es negativo.
❤😂😊
Thanks for sharing 🏴
Una distrofia, que termina en parálisis, hasta que llega al corazón. Podemos hacer mucho en el mundo para mejorar su calidad de vida.
Is the plus form available for sale yet?
This medicine available in dubai or not
BEEP!
@3:37!! WTF
Is it working only on Duchenne md, how about Emery Dreifuss??
So what happened, is there progress with Ezutromid on patients with all types of muscular dytrophy?
If A dad with 5 generations of known family members with either being a carrier or having beckers/duchene muscular dystrophy, what Percent Chance does his daughter have of being a carrier?
You know it's serious when the robot's four-line mouth frowns.
Hola..me gustaría en español por favor.. gracias!!
My young friend takes 5ml of emflaza on Friday and Saturday mornings. He has a lot of issues affecting his mental health, including a grandma that uses sugar to buy his loyalty to herself. On his emflaza days, his temper is extremely intensified. To the point of using physical violence against everyone around him. I've started to call his behavior... Roid rage.
Thank you.
When it will b available in pakistan we are waiting
Congraturations for passing trial of FDA! When do you expect that Korean Patient can access Duvyzat?
LOL, until recently I hadn't realized that Mario updated his favorite way to tackle ED and it's a relief! Although what he previously suggested was pretty good, it was a real pain to follow... I just go'ogled the latest by Mario Volpstein, it's so much simpler and potent now!
Veľmi zaujímavé
O
When will get this medicine in uae 🇦🇪
What is the moral of the session
My daughter is a manifesting patient of dmd. We all need to be part of all the treatment as well as boys because we also have same symptoms as boys do.
My daughter is a manifesting patient of dmd. We all need to be part of all the treatment as well as boys because we also have same symptoms as boys do.
Barlow's Extracts has it . I have tried their other products and they have been great so far, Im ordering some of their Epicatehin too 👍🤠🍻
Barlows Extracts has it and they seem like a very good quality business with good products...
Would this also help with Muscle antrophy too?
Is this study paper published yet?
Thank you for this informative session PPMD
Aw his little face... 🥺🤗
This is very good. Thank you all the way from India ❤
I am floored. I am also in the greater Philadelphia area, have a family history of DMD. My mom had a test done when she was pregnant with me and my male twin. At the time the test they did showed that both of us had a 95% chance of inheriting the effective gene. I shared all of this information when I went to UPenn with a genetic counselor. I was told that there was no possibility I could be affected despite my carrier status. I was diagnosed with fibromyalgia instead. I'm glad this video is here, feel very validated as a confirmed carrier that my muscle weakness is not 'just in my head'.
Emily, please feel free to reach out to our team if we can help talk through any topics or answer any questions you may have: www.parentprojectmd.org/care/for-families/ppmd-for-you-schedule-a-one-to-one-meeting/
@@ParentProjectMD Much appreciated! I certainly will!
Ya no importa, tengo el tipo de duchenne que actúa como Becker, pero no me interesa, seguiré avanzando hasta el final, y si muero moriré sabiendo que pelee hasta el final
@marioandreslopez9153 a lo que sé Duchenne es más grave no? Ya que avanza demasiado rápido en cambio Becker es mucho más lento, no?
@@monicazendejas9974 si, pero becker se puede detener ahí, duchenne puede seguir avanzando
@@marioandreslopez9153 Así es!!! Pero en tu comentario se nota que eres super fuerte y vas a lograr estar bien!!! 🤞
Please invent DMD medicine to cure DMD
Hello, are there any full-length dystrophin studies from people with girth or crisper?
Please treatment DMD ducenne muscular Dystrophy
Do Beckers patients use Agamree
No news now. Must have failed badly as a product. It happens.
Can someone older than 5 years have this treatment?
مرحبا ابني مصاب بمرض الحثل العضلي نمط دوشين ويحتاج الى مساعدة وعلاج قبل ان يتدهور الحالة
Great effort by Serapta Therapeutics and tireless effort by PPMD . Is this an option for Exon 2 Duplication
time is muscle
At $3.2m per patient, only the elite can afford such treatment!!